Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.57 |
| ▸ | TTR | P02766 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.53 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.53 |
| ▸ | PTPRC | P08575 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8882817 | 0.90 | AKR1B1 (0.56) | AKR1B1MAPK14TTRMAPTALDH1A1 | |
| SCHEMBL7832007 | 0.88 | MAPT (0.67) | AKR1B1TTRMAPTALDH1A1RAB9A | |
| SCHEMBL10922029 | 0.87 | TTR (0.55) | AKR1B1TTRMAPTALDH1A1RAB9A | |
| SCHEMBL490527 | 0.83 | MAPK14 (0.56) | AKR1B1MAPK14MAPTALDH1A1RAB9A | |
| SCHEMBL8137432 | 0.83 | SRD5A2 (0.50) | AKR1B1MAPK14TTRMAPTALDH1A1 | |
| SCHEMBL24927572 | 0.81 | SRD5A2 (0.50) | AKR1B1MAPK14TTRMAPTRAB9A | |
| SCHEMBL8143121 | 0.81 | TBXA2R (0.53) | SRD5A2SRD5A1 | |
| SCHEMBL8143124 | 0.81 | TBXA2R (0.53) | SRD5A2SRD5A1 | |
| SCHEMBL490212 | 0.80 | AKR1B1 (0.56) | AKR1B1MAPK14MAPTALDH1A1RAB9A | |
| SCHEMBL490149 | 0.80 | AKR1B1 (0.56) | AKR1B1MAPK14ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0069810-A1 | Novel dibenzoxepins, their preparation, compositions containing them and the use of dibenzoxepins in the treatment of allergic conditions | MERCK & CO. INC. (US) | 1983-01-19 | — | — | EP | claimed |
| US-8350041-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-01-08 | — | — | US | disclosed |
| US-8350041-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-01-08 | — | — | US | disclosed |
| US-8350041-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-01-08 | — | — | US | disclosed |
| US-20120095010-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095010-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095010-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R (US) | 2012-04-19 | — | — | US | disclosed |
| US-8106207-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-01-31 | — | — | US | disclosed |
| US-8106207-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-01-31 | — | — | US | disclosed |
| US-8106207-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-01-31 | — | — | US | disclosed |
| US-20090298867-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R | 2009-12-03 | — | — | US | disclosed |
| US-7589103-B2 | Especially 2-aminocarbonyl-9-(thio)xanthenylidene-8-aza-bicyclo[3.2.1] octane derivatives are used in pharmaceutical and veterinary compositions for treating mild to severe pain and various diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-15 | — | — | US | disclosed |
| US-7589103-B2 | Especially 2-aminocarbonyl-9-(thio)xanthenylidene-8-aza-bicyclo[3.2.1] octane derivatives are used in pharmaceutical and veterinary compositions for treating mild to severe pain and various diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-15 | — | — | US | disclosed |
| US-7589103-B2 | Especially 2-aminocarbonyl-9-(thio)xanthenylidene-8-aza-bicyclo[3.2.1] octane derivatives are used in pharmaceutical and veterinary compositions for treating mild to severe pain and various diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-15 | — | — | US | disclosed |
| US-20050009860-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-01-13 | — | — | US | disclosed |
| EP-0549352-B1 | Tricyclic compounds as angiotensin II antagonists | KYOWA HAKKO KOGYO KK (JP) | 2000-03-01 | — | — | EP | disclosed |
| US-5607955-A | TREATMENT OF HYPERTENSION, CONGESTIVE HEART FAILURE, RENAL FAILURE AND GLAUCOMA | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-03-04 | — | — | US | disclosed |
| US-5478840-A | Imidazo(4,5-b)pyridine derivatives used as antagonism to angiotensin ii receptors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1995-12-26 | — | — | US | disclosed |
| US-5378701-A | Angiotensin II inhibitors; hypotensive agents; congestive heart and kidney failure; glaucoma | KYOWA HAKKO KOGYO (JP) | 1995-01-03 | — | — | US | disclosed |
| EP-0549352-A2 | Tricyclic compounds as angiotensin II antagonists | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1993-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298867-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | AKR1B1 628/4885MAPK14 3917/4885TTR 2536/4885 |
| US-20120095010-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | AKR1B1 628/4885MAPK14 3917/4885TTR 2536/4885 |
| US-20050009860-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | AKR1B1 628/4885MAPK14 3917/4885TTR 2536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.